


Candriam

# Candriam Oncology Impact Acc

LU1864483166

19-05-2026

FM



## Investment objective

The fund will invest in shares of companies operating in the field of oncology (study, diagnosis, treatment, etc. of cancer) whose registered offices and/or principal activities are in the whole world. The fund seeks to achieve capital growth by investing in the principal assets traded, outperform the benchmark index and thus have a positive social long term impact, by selecting companies that take on certain societal challenges and that deploy resources in the fight against cancer.

## Fees

Entry fee	-->Tarievenkaart / Cost information sheet
Exit charges	-->Tarievenkaart / Cost information sheet
Estimated ongoing charges	1,11%

## Quote

Quote	€261,53
Quote date	18-05-2026

## Performance in EUR

Date	18-05-2026
This year	-4,34%
1 week	-0,26%
1 month	-5,51%
3 months	-5,94%
6 months	-2,01%
1 year	20,89%
3 years (annualised)	2,54%
5 years (annualised)	3,41%
Since start (annualised)	7,94%

## Dividend

Dividend paying	No
-----------------	----

## Indicators

Standard deviation (3yr)	16,00%
Share ratio (3yr)	0,13
Beta (3yr)	1,14
Alpha (3yr)	1,87
Tracking error (3yr)	7,05


## Top 10 holdings (31-10-2025)

Eli Lilly and Co	6,63 %
AstraZeneca PLC	4,28 %
Thermo Fisher Scientific Inc	3,41 %
Novartis AG Registered Shares	3,40 %
Intuitive Surgical Inc	3,28 %
Gilead Sciences Inc	3,24 %
AbbVie Inc	3,20 %
Danaher Corp	3,14 %
Amgen Inc	3,09 %
Regeneron Pharmaceuticals Inc	3,01 %

?>

## Characteristic

Asset Manager	Candriam
Asset class	Equities
Investment category	Equities - Global
Active/Passive	Active
Fund code	205143
Fund code fractional orders	-
Fund manager name	Linden Thomson Servaas Michielssens
ISIN	LU1864483166
Sustainable Classification	Art. 9, impact investing
Sustainability Rating	
Domicile	Luxembourg
Currency	EUR
Fund size (mio)	1.300,11 (15-05-2026)
Cut-off time	-
Execution date	-
Inception date	20-02-2019
Benchmark	MSCI World NR USD
Minimum investment amount	-
Assortiment	Self Directed Investing Plus, Investment advice



**General Disclaimer**

The information provided in this document has been drafted by ABN AMRO Bank N.V

**About ABN AMRO**

ABN AMRO Bank N.V. has its registered office at Gustav Mahlerlaan 10, 1082 PP Amsterdam (the Netherlands). Telephone: 0900 - 0024\*. Internet: abnamro.nl ABN AMRO Bank N.V. holds a banking licence from De Nederlandsche Bank N.V. (the Dutch central bank) and is included in the register of the Autoriteit Financiële Markten (AFM - Authority for the Financial Markets) under number 12000004. ABN AMRO Bank N.V. is entered in the Trade Register of the Amsterdam Chamber of Commerce under number 34334259. The VAT identification number of ABN AMRO Bank N.V. is NL8206.46.660B01.

**US Securities Law Disclaimer**

ABN AMRO Bank N.V. ('ABN AMRO') is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the '1934 Act') and under applicable state laws in the United States. In addition, ABN AMRO is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the 'Advisers Act' and together with the 1934 Act, the 'Acts'), and under applicable state laws in the United States. Accordingly, absent specific exemption under the Acts, any brokerage and investment advisory services provided by ABN AMRO, including (without limitation) the investment products and investment services described herein are not intended for U.S. persons. Neither this document, nor any copy thereof may be sent to or taken into the United States or distributed in the United States or to a US person. Without limiting the generality of the foregoing, the offering, sale and/or distribution of the investment products or investment services described herein is not intended in any jurisdiction to any person to whom it is unlawful to make such an offer, sale and/or distribution. Persons into whose possession this document or any copy thereof may come, must inform themselves about, and observe, any legal restrictions on the distribution of this document and the offering, sale and/or distribution of the investment products and investment services described herein. ABN AMRO cannot be held responsible for any damages or losses that occur from transactions and/or services in defiance with the restrictions aforementioned.

\* Call charges: for this call you pay your usual call charges set by your telephone provider